SAN DIEGO, May 25, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company is collaborating with leading pediatric infectious disease researchers Stuart P. Adler, M.D., and Michael A. McVoy, Ph.D., of Virginia Commonwealth University (VCU) under a five-year, approximately $4.0 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The grant will support development and animal testing of novel vaccine approaches designed to protect women of child-bearing potential from infection with cytomegalovirus (CMV). Vical will produce the DNA vaccines and Vaxfectin® adjuvant, and will conduct the animal studies funded by the grant.
